US DoJ Memos May Hint At Enforcement Stepdown

The US Department of Justice has ordered its attorneys to ask for the dismissal of more whistleblower cases, and to avoid basing civil enforcement actions solely on guidance documents. Both could lead to fewer enforcement actions against device manufacturers.

LISBON, PORTUGAL - December 9, 2014: Photo of the United States Department of Justice (DOJ) homepage on a monitor screen through a magnifying glass.

Two recent memos from the US Department of Justice indicate new policies that could lead to a lighter touch for device-industry enforcement.

The first memo, dated Jan. 10, says that government attorneys should consider dismissing whistleblower False Claims Act cases when...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

Whistleblower Suit Against UnitedHealth Continues After Semler, Bard Settle Related Cases

 
• By 

Insurance firm UnitedHealth is facing allegations the company intentionally used an unreliable PAD screening method to increase its reimbursements under Medicare Advantage. Semler Scientific and Bard, which respectively made and manufactured the products in question, settled related cases for $37m.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

 

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.

FCA Enforcement Shows No Signs of Slowing, Attorney Tells Medtech Companies

 
• By 

Federal False Claims Act settlements hit $3.8bn in the first half of fiscal 2025, with enforcement expected to intensify, Barnes & Thornburg partner Jackie Papish tells Medtech Insight. Key watch areas include qui tam cases, DEI policy implications, and growing scrutiny of diagnostics.

Oura Gets Competitors Banned From US Market, But Faces Ultrahuman Countersuit

 
• By 

The US International Trade Commission has banned smart rings from Ultrahuman and RingConn after Oura Health's patent infringement case. Ultrahuman countersued, claiming Oura infringes its intellectual property. Sales and marketing of the affected rings will cease on October 22.

More from Policy & Regulation

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By 

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By 

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.